CD8A and neoplasm: In addition, to further identify the tumor killing efficiency of the CD69+CD8+ T cells, the Panc02‐based subcutaneous tumor model was reconstructed and treated with PBS, αMSLN, PancNV and the combined (αMSLN plus PancNV) therapy, respectively.